Various targeted therapies, including anaplastic lymphoma kinase (ALK) inhibitors, mesenchymal epithelial transition (MET) inhibitors, cyclin-dependent kinase (CDK4/6) inhibitors, poly ADP-ribose polymerase inhibitors (PARP), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors, Breakpoint Cluster Region–v-Abl Abelson murine leukemia viral oncogene homolog (BCR-ABL) inhibitors, HER-2 inhibitors, and tyrosine kinase inhibitors, have been associated with pseudo-AKI. The gene discussed is ERBB2; the disease is acute kidney injury.